Stocks · Healthcare · Drug Manufacturers - General
Organon & Co. OGN
$13.72 +0.07% Close, Oct 2, 2026 · NYSE · Market cap $3.60B
Strong trendInexpensive vs sector
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $0.77, down 71.4% year over year.
- At 17.8× trailing earnings, the shares trade at the highest P/E of the company's past five years.
- Net debt is 5.7× EBITDA, a high level of leverage.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 26%
- EPS growth (TTM, YoY)Bottom 22%
- FCF growth (TTM, YoY)Bottom 44%
- Revenue growth, 3-year CAGRBottom 24%
- Revenue growth accelerationBottom 49%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 25%
- Gross marginBottom 37%
- Operating marginTop 14%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Bottom 35%
- Net debt / EBITDA (lower is better)Bottom 12%
- Interest coverTop 35%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 8%
- Free-cash-flow yieldTop 4%
- EBITDA / enterprise valueTop 6%
- Sales / enterprise valueTop 23%
- P/E vs own 5-year history (lower is better)Bottom 3%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 47%
- 6-month returnTop 6%
- 1-year return vs S&P 500Top 40%
- Distance from 52-week highTop 1%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 34%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 2%
- Upside to consensus price targetBottom 8%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 1%
- Maximum drawdown, 3 yearsBottom 42%
- Beta vs S&P 500 (lower is better)Top 38%
- Net debt / EBITDA (lower is better)Bottom 12%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -2.1% | -2.5% | ↓ |
| EPS growth (YoY) | -67.7% | -71.4% | ↓ |
| Gross margin | 56.3% | 53.0% | ↓ |
| Operating margin | 21.3% | 19.3% | ↓ |
| FCF margin | 7.7% | 8.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -2.5% | -2.1% | ↓ | Bottom 26% |
| EPS growth (TTM, YoY) | -71.4% | -67.7% | ↓ | Bottom 22% |
| Gross margin | 53.0% | 56.3% | ↓ | Bottom 37% |
| Operating margin | 19.3% | 21.3% | ↓ | Top 14% |
| Net margin | 3.4% | 11.1% | ↓ | — |
| Free-cash-flow margin | 8.1% | 7.7% | ↑ | — |
| Return on invested capital | 4.7% | — | Top 25% | |
| Revenue growth, 3-year CAGR | 0.2% | — | Bottom 24% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +1.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 5.68×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 2.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.50%
- Net buyback yield (TTM)
- 0.03%
- Shareholder yield
- 0.53%
- Share count change, 1 year
- +4.0%
- Share count change, 3-year CAGR
- +1.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 31, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -4.9%
- Average 2-day reaction, last 8
- -2.4%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $13.00
- Target vs current price
- -5.2%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 22%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 31, 2026 | +0.0% | +0.0% | +0.0% | +1.5% | — |
| Apr 30, 2026 | -14.5% | -0.7% | +0.5% | +0.1% | +1.5% |
| Feb 12, 2026 | -13.7% | -8.2% | -2.2% | -17.7% | +73.6% |
| Nov 10, 2025 | +8.6% | +13.7% | +11.1% | +7.5% | +19.5% |
| Aug 5, 2025 | +6.4% | -13.1% | -6.8% | -2.6% | -31.1% |
| May 1, 2025 | +14.6% | -26.9% | -32.3% | -26.2% | -22.9% |
| Feb 13, 2025 | -2.2% | +11.0% | +6.7% | +1.8% | -40.7% |
| Oct 31, 2024 | -3.3% | +4.7% | -11.9% | -10.9% | -11.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 31, 2026 | $0.85 | $0.85 | +0.0% | $1.60B |
| Apr 30, 2026 | $0.71 | $0.83 | -14.5% | $1.46B |
| Feb 12, 2026 | $0.63 | $0.73 | -13.7% | $1.51B |
| Nov 10, 2025 | $1.01 | $0.93 | +8.6% | $1.60B |
| Aug 5, 2025 | $1.00 | $0.94 | +6.4% | $1.59B |
| May 1, 2025 | $1.02 | $0.89 | +14.6% | $1.51B |
| Feb 13, 2025 | $0.90 | $0.92 | -2.2% | $1.59B |
| Oct 31, 2024 | $0.87 | $0.90 | -3.3% | $1.58B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 17.8× | 5.8× | 100th | Top 8% |
| P/E (forward) | 4.1× | — | — | — |
| EV / EBITDA | 8.4× | — | — | Top 6% |
| EV / Sales | 1.80× | — | — | Top 23% |
| Free-cash-flow yield | 13.82% | — | — | Top 4% |
| Earnings yield | 5.61% | — | — | Top 8% |
P/E over the past five years
Range 3.2× – 17.6× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +24.8%
- Earnings per share growth (TTM)
- -71.4%
- Change in P/E multiple
- +443.2%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 122
- Days above the 200-day average
- 122
- 50-day average slope (20 days)
- +0.5%
- 200-day average slope (20 days)
- +6.2%
- Distance from 50-day average
- +0.3%
- Distance from 200-day average
- +26.0%
- RSI (14)
- 55.0
- Relative volume
- 0.77×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 2.7%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.91
- Correlation with S&P 500
- 0.24
- Current drawdown from 1-year high
- -0.4%
- Maximum drawdown, 3 years
- -75.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 2, 2022 | Mar 30, 2026 | -85.5% | 1022 days | Not yet recovered |
| May 24, 2021 | Jun 9, 2021 | -25.1% | 11 days | 184 days (Mar 2, 2022) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.60B
- P/E (TTM)
- 17.8
- EPS, diluted (TTM)
- $0.77
- Revenue (TTM)
- $6.13B
- Dividend yield
- 0.58%
- 52-week range
- $5.69 – $13.79
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Gross profit | $3.92B | $3.88B | $3.75B | $3.71B | $3.36B |
| Operating income | $1.92B | $1.71B | $1.33B | $1.49B | $1.28B |
| Net income | $1.35B | $917.0M | $1.02B | $864.0M | $187.0M |
| EPS (diluted) | $5.33 | $3.59 | $3.99 | $3.33 | $0.72 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.58B | $1.59B | $1.51B | $1.59B | $1.60B | $1.51B | $1.46B | $1.56B |
| Net income | $359.0M | $109.0M | $87.0M | $145.0M | $160.0M | -$205.0M | $146.0M | $108.0M |
| EPS (diluted) | $1.38 | $0.42 | $0.33 | $0.56 | $0.61 | -$0.79 | $0.55 | $0.40 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $2.46B | $858.0M | $799.0M | $939.0M | $700.0M |
| Capital expenditure | -$488.0M | -$427.0M | -$261.0M | -$351.0M | -$162.0M |
| Free cash flow | $1.97B | $431.0M | $538.0M | $588.0M | $538.0M |
| Dividends paid | -$145.0M | -$290.0M | -$294.0M | -$297.0M | -$88.0M |
| Net share buybacks | $0 | $0 | -$17.0M | -$22.0M | $0 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.13B
- Total assets
- $13.18B
- Total liabilities
- $12.17B
- Total debt
- $8.55B
- Net debt
- $7.42B
- Shareholders’ equity
- $1.01B
As of Jun 30, 2026 (filed Jul 31, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Aug 14, 2026 | $0.02 | Sep 10, 2026 |
| May 11, 2026 | $0.02 | Jun 11, 2026 |
| Feb 23, 2026 | $0.02 | Mar 12, 2026 |
| Nov 20, 2025 | $0.02 | Dec 11, 2025 |
| Aug 15, 2025 | $0.02 | Sep 11, 2025 |
| May 12, 2025 | $0.02 | Jun 12, 2025 |
| Feb 24, 2025 | $0.28 | Mar 13, 2025 |
| Nov 12, 2024 | $0.28 | Dec 12, 2024 |
Short interest
- Shares sold short
- 17,529,739
- Days to cover
- 5.53
- Change vs previous report
- +5.0%
FINRA short interest, settlement date Sep 15, 2026.